Zobrazeno 1 - 10
of 496
pro vyhledávání: '"Alan P. Venook"'
Autor:
Travis Zack, Kurt P. Losert, Samantha M. Maisel, Jennifer Wild, Amin Yaqubie, Michael Herman, Jennifer J. Knox, Robert J. Mayer, Alan P. Venook, Atul Butte, Allison F. O’Neill, Ghassan K. Abou-Alfa, John D. Gordan
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-6 (2023)
Abstract The incidence and biochemical consequences of rare tumor subtypes are often hard to study. Fibrolamellar liver cancer (FLC) is a rare malignancy affecting adolescents and young adults. To better characterize the incidence and biochemical con
Externí odkaz:
https://doaj.org/article/a6be12a913714c2aaed7398302e34be1
Autor:
Nicholas Fidelman, Chloe E. Atreya, Madeline Griffith, M. Alexandra Milloy, Julia Carnevale, Pelin Cinar, Alan P. Venook, Katherine Van Loon
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Extrahepatic disease progression limits clinical efficacy of Yttrium-90 (90Y) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Trifluridine and tipiracil (TAS-102) has overall
Externí odkaz:
https://doaj.org/article/2d744165fd454412a9fa0371b04c5e54
Autor:
Radia M. Johnson, Xueping Qu, Chu-Fang Lin, Ling-Yuh Huw, Avinashnarayan Venkatanarayan, Ethan Sokol, Fang-Shu Ou, Nnamdi Ihuegbu, Oliver A. Zill, Omar Kabbarah, Lisa Wang, Richard Bourgon, Felipe de Sousa e Melo, Chris Bolen, Anneleen Daemen, Alan P. Venook, Federico Innocenti, Heinz-Josef Lenz, Carlos Bais
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)
ARID1A is an epigenetic regulator mutated in approximately 5% of non-hypermutated colorectal cancer tumors, however, its relationship with treatment response remains to be explored. Here, the authors suggest that ARID1A mutations may confer intrinsic
Externí odkaz:
https://doaj.org/article/4488b89ca7bf43bdb1d09041a86d2a0c
Autor:
Fang-Shu Ou, Daniel H. Ahn, Jesse G. Dixon, Axel Grothey, Yiyue Lou, Pashtoon M. Kasi, Joleen M. Hubbard, Eric Van Cutsem, Leonard B. Saltz, Hans-Joachim Schmoll, Richard M. Goldberg, Alan P. Venook, Paulo Hoff, Jean-Yves Douillard, J. Randolph Hecht, Herbert Hurwitz, Cornelis J. A. Punt, Miriam Koopman, Carsten Bokemeyer, Charles S. Fuchs, Eduardo Diaz-Rubio, Niall C. Tebbutt, Chiara Cremolini, Fairooz F. Kabbinavar, Tanios Bekaii-Saab, Benoist Chibaudel, Takayuki Yoshino, John Zalcberg, Richard A. Adams, Aimery de Gramont, Qian Shi
Publikováno v:
Cancers, Vol 15, Iss 16, p 4117 (2023)
Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consider
Externí odkaz:
https://doaj.org/article/ce222f9467be42278701433a1ee37c17
Autor:
Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Background: The mammalian target of rapamycin (mTOR) pathway is upregulated in nearly half of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the combination of mTOR pathway inhibition with t
Externí odkaz:
https://doaj.org/article/cbb627c3bf394483ab5c3ac74db1bf71
Autor:
Hannah M. Dragomanovich, Anand Dhruva, Eve Ekman, Kelly L. Schoenbeck, Ai Kubo, Erin L. Van Blarigan, Hala T. Borno, Mikaela Esquivel, Bryant Chee, Matthew Campanella, Errol J. Philip, John P. Rettger, Blake Rosenthal, Katherine Van Loon, Alan P. Venook, Christy Boscardin, Patricia Moran, Frederick M. Hecht, Chloe E. Atreya
Publikováno v:
Global Advances in Health and Medicine, Vol 10 (2021)
Purpose A metastatic cancer diagnosis is associated with high levels of distress in patients and caregivers, which may be alleviated by mindfulness interventions. Research on scalable, tailored, online mindfulness training programs is needed. We soug
Externí odkaz:
https://doaj.org/article/c7915925f8f748679a077124e599447e
Autor:
Erin L. Van Blarigan, Hilary Chan, Katherine Van Loon, Stacey A. Kenfield, June M. Chan, Emily Mitchell, Li Zhang, Alan Paciorek, Galen Joseph, Angela Laffan, Chloe E. Atreya, Yoshimi Fukuoka, Christine Miaskowski, Jeffrey A. Meyerhardt, Alan P. Venook
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Over 1.3 million people live with colorectal cancer in the United States. Physical activity is associated with lower risk of colorectal cancer recurrence and mortality. Interventions are needed to increase physical activity in col
Externí odkaz:
https://doaj.org/article/47f55795a9714608bba475e9c67e42bb
Autor:
Kimberly P. Rogers, Victoria G. Morris, Erica E. Fortune, Andrea Goodman, Kim Newcomer, M. Susan Pfau, Christine L. Sardo Molmenti, Cynthia A. Thomson, Alan P. Venook, Melissa F. Miller
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:HSR23-116
Autor:
M. Margaret Kemeny, Fengmin Zhao, Arlene A. Forastiere, Paul Catalano, Stanley R. Hamilton, Brent W. Miedema, Nancy A. Dawson, Louis M. Weiner, Brian D. Smith, Bernard A. Mason, Stephen L. Graziano, Paul B. Gilman, Alan P. Venook, Harlan A. Pinto, Robert P. Whitehead, Peter J. O’Dwyer, Al B. Benson
Publikováno v:
Annals of Surgical Oncology. 30:1099-1109
Background Studies suggest that adjuvant chemotherapy should be initiated at the earliest possible time. The Eastern Cooperative Oncology Group (ECOG) and Intergroup evaluated the effect of perioperative fluorouracil (5-FU) on overall survival (OS) f
Autor:
Nadine J. McCleary, Sui Zhang, Chao Ma, Fang-Shu Ou, Tiffany M. Bainter, Alan P. Venook, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, Bert H. O'Neil, Blase N. Polite, Howard S. Hochster, James N. Atkins, Richard M. Goldberg, Kimmie Ng, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt
Publikováno v:
J Geriatr Oncol
BACKGROUND: Little is known about the interaction of comorbidities and age on survival outcomes in colorectal ancer (mCRC), nor how comorbidities impact treatment tolerance. METHODS: We utilized a cohort of 1,345 mCRC patients enrolled in CALGB/SWOG